(Q27007083)

15

0 references

Julián Panés

13

0 references

Geert D'Haens

7

object named as

Geert D'Haens

0 references

Brian G. Feagan

6

object named as

Brian Feagan

1 reference

16

Remo Panaccione

1 reference

9

Walter Reinisch

1 reference

14

Edouard Louis

1 reference

5

Pal Miheller

1 reference

1

Pavol Papay

1 reference

12

Laurence Egan

1 reference

Ana Ignjatovic

2

1 reference

Konstantinos Karmiris

3

1 reference

Heda Amarante

4

1 reference

Philippe Marteau

8

1 reference

Andreas Sturm

10

1 reference

Flavio Steinwurz

11

1 reference

language of work or name

1 reference

September 2013

1 reference

Journal of Crohn's and Colitis

published in

1 reference

volume

7

1 reference

issue

8

1 reference

page(s)

653-69

1 reference

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestiv

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Development of the Crohn's disease digestive damage score, the Lémann score

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Implementing changes in clinical practice to improve the management of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Use of the Crohn's disease activity index in clinical trials of biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

An index of inflammatory activity in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

C-reactive protein as a marker for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Review of fecal biomarkers in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Laboratory markers in IBD: useful, magic, or unnecessary toys?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Reproducibility of bowel ultrasonography in the evaluation of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Assessment of inflammatory and fibrotic stenoses in patients with Crohn's disease using contrast-enhanced ultrasound and computerized algorithm: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

CT enterography of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Diagnostic and prognostic significance of serum C-reactive protein levels in patients admitted to the department of medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Laboratory evaluation of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Non-perforating small bowel Crohn's disease assessed by MRI enterography: derivation and histopathological validation of an MR-based activity index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Comparison of magnetic resonance enterography with endoscopy, histopathology, and laboratory evaluation in pediatric Crohn disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

MRI in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Postoperative recurrent luminal Crohn's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

C-reactive protein and monitoring the activity of Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

High-sensitivity C-reactive protein in paediatric inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Surgery for acute Crohn's colitis: results and long term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Crohnʼs disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn's disease: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

The inflammatory bowel disease questionnaire: a review of its national validation studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index in Crohn's disease and measures of utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Bowel magnetic resonance imaging of pediatric patients with oral mannitol MRI compared to endoscopy and intestinal ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Magnetic resonance imaging in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

MR enterography versus capsule endoscopy in paediatric patients with suspected Crohn’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2013.02.005